Top

Published in:

01-07-2018 | Original Research Paper

Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH)

Authors: Irene Paterniti, Michela Campolo, Marika Cordaro, Rosalba Siracusa, Antonio Filippone, Emanuela Esposito, Salvatore Cuzzocrea

Published in: Inflammation Research | Issue 7/2018

Abstract

Objective and design

To characterize the impact of inflammatory process and oxidative stress in the degree of benign prostatic hyperplasia (BPH), a common condition in which chronic inflammation plays a crucial role, we investigated the effect of different plant extract preparations in an in vivo model of BPH as new therapeutic target.

Material

BPH was made in rats with daily administration of testosterone propionate (3 mg/kg) for 14 days.

Treatment

Rats were randomized into different groups to receive oral administration of plant extract preparations: Serenoa repens with selenium (SeR 28.5 mg/kg associated with Se 0.005 mg/kg), Teoside (2 mg/kg), and Puryprost (14 mg/kg containing Teoside 50% 2 mg/kg and Epilobium 12 mg/kg).

Methods

After 14 days, rats were killed and histological changes, prostate weight and apoptotic pathways were assayed.

Results

The results obtained demonstrated that the association of treatments reduced prostate weight and hyperplasia, while treatment with Puryprost demonstrated a greater trend of protection compared to the other treatments.

Conclusion

Thus, our results indicate that plant extract could be considered as new useful therapy in the treatment of BPH with particular attention on Puryprost that represents a rational approach to reduce BPH through modulation of inflammatory process and anti-oxidant process.

Kessler OJ, Keisari Y, Servadio C, Abramovici A. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol. 1998;159(3):1049–53.CrossRefPubMed

Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1784–91.CrossRefPubMed

Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–16. https://doi.org/10.1016/j.eururo.2006.12.011.CrossRefPubMed

Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008;108(3–5):254–60. https://doi.org/10.1016/j.jsbmb.2007.09.013.CrossRefPubMed

Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004;7(2):155–69.CrossRefPubMed

Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30(3):227–81. https://doi.org/10.1038/aps.2009.1.CrossRefPubMed

Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, et al. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of Serenoa repens, selenium and lycopene. J Biomed Sci. 2014;21:19. https://doi.org/10.1186/1423-0127-21-19.CrossRefPubMedPubMedCentral

Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014;28(7):949–55.CrossRefPubMed

Granica S, Piwowarski JP, Czerwinska ME, Kiss AK. Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review. J Ethnopharmacol. 2014;156:316 – 46. https://doi.org/10.1016/j.jep.2014.08.036.CrossRefPubMed

10.

Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42–56. https://doi.org/10.1016/j.lfs.2015.01.023.CrossRefPubMed

11.

Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol. 2012;167(1):95–108. https://doi.org/10.1111/j.1476-5381.2012.01969.x.CrossRefPubMedPubMedCentral

12.

Paterniti I, Impellizzeri D, Di Paola R, Esposito E, Gladman S, Yip P, et al. Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies. J Neuroinflammation. 2014;11:6. https://doi.org/10.1186/1742-2094-11-6.CrossRefPubMedPubMedCentral

13.

Cordaro M, Paterniti I, Siracusa R, Impellizzeri D, Esposito E, Cuzzocrea S. KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. Mol Neurobiol. 2016. https://doi.org/10.1007/s12035-016-9827-0.CrossRefPubMed

14.

Paterniti I, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Galuppo M, et al. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. J Neurochem. 2010;112(3):611–24. https://doi.org/10.1111/j.1471-4159.2009.06471.x.CrossRefPubMed

15.

Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics 2004 CA: a cancer journal for clinicians. 2004;54(1):8–29.

16.

Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496–501. https://doi.org/10.1016/j.juro.2012.03.125.CrossRefPubMedPubMedCentral

17.

Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173(4):1309–13. https://doi.org/10.1097/01.ju.0000152318.79184.6f.CrossRefPubMed

18.

Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178(2):395–401. https://doi.org/10.1016/j.juro.2007.03.103.CrossRefPubMed

19.

Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562–8. https://doi.org/10.1210/jc.2005-2799.CrossRefPubMedPubMedCentral

20.

Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014;74(6):669–79. https://doi.org/10.1002/pros.22785.CrossRefPubMedPubMedCentral

21.

Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 2010;85(3):328–33. https://doi.org/10.1159/000315064.CrossRefPubMed

22.

Naber KG, Weidner W. Chronic prostatitis-an infectious disease? J Antimicrob Chemother. 2000;46(2):157–61.CrossRefPubMed

23.

Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26(7):1170–81. https://doi.org/10.1093/carcin/bgh317.CrossRefPubMed

24.

Larre S, Camparo P, Comperat E, Boulbes D, Haddoum M, Baulande S, et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012;14(3):499–504. https://doi.org/10.1038/aja.2011.132.CrossRefPubMed

25.

Khan N, Adhami VM, Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer. 2009;61(6):836–41. https://doi.org/10.1080/01635580903285056.CrossRefPubMedPubMedCentral

26.

Cordaro M, Impellizzeri D, Siracusa R, Gugliandolo E, Fusco R, Inferrera A, et al. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. Toxicol Appl Pharmacol. 2017;329:231–40. https://doi.org/10.1016/j.taap.2017.06.005.CrossRefPubMed

27.

Larre S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, et al. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 2008;87(1–4):14–9. https://doi.org/10.1016/j.prostaglandins.2008.05.001.CrossRefPubMed

28.

Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005;25(4):3123–33.PubMed

Title: Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH)
Authors: Irene Paterniti
Michela Campolo
Marika Cordaro
Rosalba Siracusa
Antonio Filippone
Emanuela Esposito
Salvatore Cuzzocrea
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: Inflammation Research / Issue 7/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-018-1152-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH)

Abstract

Objective and design

Material

Treatment

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective and design

Material

Treatment

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Soluble TREM-1 as a predictive factor of neonatal sepsis: a meta-analysis

Expression analysis of toll-like receptors of Dengue-infected cornea by real-time polymerase chain reaction

Inflammation, a significant player of Ataxia–Telangiectasia pathogenesis?

Biological therapy downregulates the heterodimer S100A8/A9 (calprotectin) expression in psoriatic patients

A review on heme oxygenase-1 induction: is it a necessary evil

Genistein modulates the expression of Toll-like receptors in experimental autoimmune encephalomyelitis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page